OrisDX Opens Early Access Program for Oro Lesion: The First Non-Invasive Salivary DNA Test for Oral Cancer Detection

Dental Practices Can Now Secure Priority Shipment for the Revolutionary Oral Cancer Molecular Diagnostic Test Ahead of National Commercial Launch.

CHICAGO, IL, UNITED STATES, August 26, 2026 /EINPresswire.com/ — OrisDX, a pioneer in molecular salivary diagnostics born from the University of Chicago, today announced the official opening of its Early Access Program for Oro Lesion. Designed to empower dental hygienists and clinicians as the front line of defense against oral cancer, the program allows practices to reserve sample collection kits at no cost for immediate delivery upon the upcoming commercial launch.

Providers can register their office today using the Oro Lesion early adopters form.

Current oral cancer screening relies heavily on visual-tactile exams, which can be unreliable and don’t account for molecular changes that appear far before a lesion is visible. With late-stage detection rates surging, Oro Lesion provides a critical shift from sight to science, utilizing Next-Generation Sequencing (NGS) and AI to detect somatic mutations with 93% sensitivity and 99% specificity1.

“Early detection is one of the most powerful tools we have to improve survival rates in oral cancer, as late-stage diagnosis remains far too common. The early adopters are pioneers helping to redefine how oral cancer is detected and diagnosed. Together, we are moving the needle from late-stage identification to proactive, early action that saves lives.”
– Dr. Nishant Agrawal, Department Chair of Otolaryngology – Head and Neck Surgery, The University of Chicago

Oro Lesion seamlessly integrates into routine dental hygiene workflows, requiring no specialized equipment or intensive training. The process involves:

1. A painless, 2-minute “swish and gargle” saline rinse.
2. Samples are sent to a CLIA-certified lab for ultra-sensitive genomic analysis of a patient’s salivary DNA.
3. Providers receive accurate, actionable results within 14 days via the Oris Bridge platform to guide patient care and transition to specialists.

“The most powerful healthcare innovations are those that move us from reacting to disease to anticipating it. By combining molecular science with a simple, non-invasive screening experience, Oro Lesion has the potential to transform oral cancer detection and improve outcomes for countless patients through earlier intervention and more informed clinical decision-making.”
– Dr. Amisha Singh, DDS, EdD

How to Join
Providers and practice owners can sign up for the Early Access Program by submitting the form here: Sign Up for Early Access

1. Shanmugam et al., “Ultrasensitive detection of tumor-specific mutations in saliva of patients with oral cavity squamous cell carcinoma,” Cancer (Wiley/American Cancer Society), 2021.

Nathan Steltzer
OrisDX
email us here

Media gallery